Drugs / IBI318
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04635527 | Dec 2020 → Aug 2021 | hepatocellular carcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04672928 | Dec 2020 → Jan 2023 | small cell lung carcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03875157 | Apr 2019 → Feb 2023 | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04611321 | Dec 2020 → Mar 2023 | skin squamous cell carcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04602065 | Nov 2020 → Feb 2023 | extranodal nasal NK/T cell lymphoma | Innovent Biologics (Suzhou) Co. Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT04777084 | Aug 2021 → Dec 2024 overdue | non-small cell lung carcinoma | Hunan Province Tumor Hospital | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-06-02 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Announces the Preliminary Results of the Anti-PD-1/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study innoventbio.com ↗
Twelve subjects had at least 1 tumor assessment, and 9 subjects received IBI318 treatment at doses of 10 mg and above, with 3 subjects experiencing an objective response. |
| 2019-02-07 | Innovent Biologics (Suzhou) Co. Ltd. | Regulatory Innovent Receives IND Approval of a Bispecific Antibody (IBI318) by the NMPA innoventbio.com ↗
The IND approval of IBI318 by the NMPA highlights the significant progress Innovent has made in innovative immuno-oncology. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-06-02 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Announces the Preliminary Results of the Anti-PD-1/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study innoventbio.com ↗ |
| 2019-04-24 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Announces First Patient Dosed in Phase I Clinical Trial of IBI318 Bispecific Antibody in China innoventbio.com ↗ |
| 2019-02-07 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Receives IND Approval of a Bispecific Antibody (IBI318) by the NMPA innoventbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI318 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04602065 ↗ |
| Action | Inhibit | “anti-PD1/PD-L1” NCT04602065 ↗ |
| Route | Intravenous | “0.3 mg intravenous infusion” NCT03875157 ↗ |